Cortexyme appoints dr. philip low to its board of directors

South san francisco, calif.--(business wire)--cortexyme, inc. (nasdaq: crtx), a clinical-stage biopharmaceutical company pioneering therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the appointment of dr. philip s. low, a renowned targeted drug discovery researcher and veteran biotech entrepreneur, to the company's board of directors. “in conjunction with today's acquisition of novosteo, we are very pleased to welcome a distinguished r
QNCX Ratings Summary
QNCX Quant Ranking